23 Spam-Free Article(s) Found
Article Searches
Remdesivir Gets Emergency Approval: What's In Store for Gilead? http://www.zacks.com/stock/news/912891/remdesivir-gets-emergency-approval-whats-in-store-for-gilead?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-912891 May 04, 2020 - In a short span of time, Gilead's Remdesivir has been successful in treating some coronavirus patients. But will this give a boost to the pharmaceutical giant?
Amgen (AMGN) Q1 Earnings Top, to Study Otezla for Coronavirus http://www.zacks.com/stock/news/910436/amgen-amgn-q1-earnings-top-to-study-otezla-for-coronavirus?cid=CS-ZC-FT-analyst_blog|earnings_article-910436 May 01, 2020 - Amgen (AMGN) beats estimates for both earnings and sales. It maintains its previously-issued financial guidance for 2020.
Amgen Inc (AMGN) Q1 2020 Earnings Call Transcript https://www.fool.com/earnings/call-transcripts/2020/05/01/amgen-inc-amgn-q1-2020-earnings-call-transcript.aspx?source=iedfolrf0000001 May 01, 2020 - AMGN earnings call for the period ending March 31, 2020.
Amgen Inc. (AMGN) CEO Bob Bradway on Q1 2020 Results - Earnings Call Transcript https://seekingalpha.com/article/4341844-amgen-inc-amgn-ceo-bob-bradway-on-q1-2020-results-earnings-call-transcript?source=feed_sector_healthcare May 01, 2020 - Amgen Inc. (NASDAQ:AMGN) Q1 2020 Earnings Conference Call April 30, 2020 5:30 PM ET Company Participants Arvind Sood - Vice President of Investor Relations Bob Bradway - Chief Executive Officer Dave R
Is a Beat in Store for Amarin (AMRN) This Earnings Season? http://www.zacks.com/stock/news/898431/is-a-beat-in-store-for-amarin-amrn-this-earnings-season?cid=CS-ZC-FT-analyst_blog|earnings_preview-898431 Apr 29, 2020 - Amarin's (AMRN) first-quarter results are likely to reflect strong demand for its cardiovascular drug, Vascepa.
3 Coronavirus Stocks to Buy Now https://www.fool.com/investing/2020/04/26/3-coronavirus-stocks-to-buy-now.aspx?source=iedfolrf0000001 Apr 26, 2020 - These companies are trying for coronavirus success -- but their commercialized products offer revenue no matter what.
Will Pfizer's (PFE) BioPharma Unit Q1 Earnings Increase? http://www.zacks.com/stock/news/887532/will-pfizers-pfe-biopharma-unit-q1-earnings-increase?cid=CS-ZC-FT-analyst_blog|earnings_preview-887532 Apr 24, 2020 - In Pfizer's (PFE) Biopharma unit, oncology sales are likely to have risen in the first quarter, while in non-oncology, Xeljanz and Eliquis alliance revenues are likely to have supported the top line.
Roche (RHHBY) Q1 Sales Grow on Solid Performance of New Drugs http://www.zacks.com/stock/news/883666/roche-rhhby-q1-sales-grow-on-solid-performance-of-new-drugs?cid=CS-ZC-FT-analyst_blog|earnings_article-883666 Apr 22, 2020 - Solid sales of Roche's (RHHBY) new drugs in the first quarter more than offset the competition from biosimilars.
Biotech ETF (BBH) Hits New 52-Week High http://www.zacks.com/stock/news/880288/biotech-etf-bbh-hits-new-52-week-high?cid=CS-ZC-FT-etf_news_and_commentary-880288 Apr 20, 2020 - This biotech ETF hits a new 52-week high. Are more gains in store for this ETF?
Gilead's (GILD) Coronavirus Drug Shows Promise, Shares Gain http://www.zacks.com/stock/news/876070/gileads-gild-coronavirus-drug-shows-promise-shares-gain?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-876070 Apr 17, 2020 - Treatment with Gilead's (GILD) experimental antiviral, remdesivir, shows rapid recoveries in fever and respiratory symptoms in COVID-19 patients in a Chicago hospital.

Pages: 123

Page 1>